Relacorilant(Relacorilant) - 药物靶点：GR_在研适应症：库欣综合征，腹膜癌，铂耐药性输卵管癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Relacorilant (USAN)、CORT-125134、CORT125134

靶点

GR

作用方式

拮抗剂

作用机制

GR拮抗剂(糖皮质激素受体拮抗剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [2]

在研适应症

库欣综合征腹膜癌铂耐药性输卵管癌+ [11]

非在研适应症

转移性胰腺导管腺癌

原研机构

Corcept Therapeutics, Inc.

在研机构

Corcept Therapeutics, Inc.

非在研机构-

最高研发阶段申请上市

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C27H22F4N6O3S

InChIKeyWANIDIGFXJFFEL-SANMLTNESA-N

CAS号1496510-51-0

关联

24

项与 Relacorilant 相关的临床试验

NCT06906341

/ Not yet recruiting临床2期

A Phase 2 Study of Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA)

This is a Phase 2, single-arm, open-label study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.

开始日期2025-04-01

申办/合作机构

Corcept Therapeutics, Inc.

NCT05726292

/ Recruiting临床2期IIT

A Randomized Phase II Trial of Neoadjuvant Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.

开始日期2025-01-06

申办/合作机构

The University of Chicago

NCT05257408

/ Active, not recruiting临床3期

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

开始日期2022-06-29

申办/合作机构

Corcept Therapeutics, Inc.

[+1]

100 项与 Relacorilant 相关的临床结果

登录后查看更多信息

100 项与 Relacorilant 相关的转化医学

登录后查看更多信息

100 项与 Relacorilant 相关的专利（医药）

登录后查看更多信息

35

项与 Relacorilant 相关的文献（医药）

2024-11-04·ONCOLOGIST

Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study

Article

作者: Leal, Alexis D ; Skeel, Roland T ; Fountzilas, Christos ; Pashova, Hristina ; Mann, Grace ; Oberstein, Paul E ; Alese, Olatunji B ; Huyck, Timothy K ; Noonan, Anne M ; Kio, Ebenezer A ; Chiorean, Elena Gabriela ; Bahary, Nathan ; Borazanci, Erkut H ; Lee, Valerie ; Chung, Vincent ; Philip, Philip A ; Wainberg, Zev A ; Hanna, Wahid T ; Cardin, Dana B

Abstract:

Background:

Modulation of glucocorticoid receptor (GR) activity in tumor cells enhances chemotherapy efficacy. We evaluated the selective GR modulator relacorilant plus nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who had received at least 2 prior therapy lines.

Patients and Methods:

In this open-label, single-arm, phase III study, patients received once-daily oral relacorilant (100 mg, titrated to 150 mg in 25 mg increments/cycle) and nab-paclitaxel (80 mg/m2) on days 1, 8, and 15 of 28-day cycles. The primary efficacy endpoint was objective response rate (ORR) by blinded independent central review. Progression-free survival (PFS), overall survival (OS), target gene modulation, and safety were also assessed.

Results:

Of 43 patients enrolled, 31 were evaluable for ORR (12 did not reach first postbaseline radiographic assessment). An interim analysis to assess whether ORR was ≥10% showed no confirmed responses and the study was discontinued. Two (6.5%) patients attained unconfirmed partial responses and 15 (48.4%) had stable disease. Fourteen of 31 (45.2%) patients had reductions in target lesion size, despite prior nab-paclitaxel exposure in 12 of the 14. Median PFS and OS were 2.4 months (95% CI, 1.4-4.2) and 3.9 months (95% CI, 2.8-4.9), respectively. The most common adverse events were fatigue and nausea. RNA analysis confirmed that relacorilant plus nab-paclitaxel suppressed 8 cortisol target genes of interest.

Conclusion:

Relacorilant plus nab-paclitaxel showed modest antitumor activity in heavily pretreated patients with mPDAC, with no new safety signals. Studies of this combination in other indications with a high unmet medical need are ongoing.

2024-08-02·Expert Review of Anticancer Therapy

Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives

Review

作者: Marchetti, Claudia ; Ghizzoni, Viola ; Salutari, Vanda ; Scambia, Giovanni ; Vertechy, Laura ; Giudice, Elena ; Fagotti, Anna ; Sassu, Carolina Maria ; Carbone, Maria Vittoria

INTRODUCTION:

Relacorilant (CORT125134, Corcept Therapeutics) is a selective glucocorticoid receptor modulator, which reverses the glucocorticoid-mediated anti-apoptotic effects and restores the taxane chemosensitivity in epithelial ovarian cancer cells. Given those preclinical findings, relacorilant is currently under investigation in clinical trials in combination with nab-paclitaxel for the platinum-resistant ovarian cancer setting.

AREAS COVERED:

Already published preclinical and clinical evidence of relacorilant antitumor activity was analyzed and discussed. Ongoing clinical trials registered on clincaltrials.gov were also reported. The review aimed to summarize the status of relacorilant, the mechanism of action, the published and ongoing trials, and its safety and efficacy.

EXPERT OPINION:

Relacorilant combined with nab-paclitaxel, may represent a promising strategy for the treatment of platinum-resistant ovarian cancer patients. After preliminary positive results in terms of clinical efficacy, a randomized phase III trial is ongoing to confirm the findings from the published phase II study.

2024-06-03·Clinical cancer research : an official journal of the American Association for Cancer Research

A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer

Article

作者: O'Donnell, Peter H. ; Szmulewitz, Russell Z. ; Serritella, Anthony V. ; Stadler, Walter M. ; Sweis, Randy F. ; Desai, Kunal B.

Abstract:

Purpose::

The majority of patients with metastatic prostate cancer who receive androgen-deprivation therapy and androgen receptor (AR) signaling inhibitors (ARSI) progress. Activation of the glucocorticoid receptor (GR) is associated with ARSI resistance. This single-arm phase I trial assessed safety and pharmacokinetic (PK) feasibility of a combined AR antagonist (enzalutamide) and selective GR modulator (relacorilant) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Patients and Methods::

This was a phase I trial (NCT03674814) of relacorilant and enzalutamide in patients with refractory mCRPC enrolled using a 6+3 design. The enzalutamide dose was kept constant at 120 mg/d with escalating doses of relacorilant based on safety and PK measures in cohorts of ≥6 patients. The primary objective was safety and establishment of pharmacologically active doses. Secondary objectives were related to antitumor activity.

Results::

Thirty-five patients with mCRPC were enrolled. Twenty-three were accrued across three dose cohorts in the dose-escalation phase, and 12 enrolled at the recommended phase II dose. The combination was generally well tolerated, safe, and achieved desirable enzalutamide PK. RP2D of 120 + 150 mg/d, respectively, was established. Median time on study was 2.2 months with four patients remaining on study for longer than 11 months. Four of 12 evaluable patients had a prostate-specific antigen (PSA) partial response.

Conclusions::

This is the first prospective trial combining an AR antagonist and a nonsteroidal selective GR modulator. The combination was safe and well tolerated with PSA response and prolonged disease control observed in a limited subset of patients. Further prospective trials are justified to evaluate efficacy and identify predictive biomarkers of response.

47

项与 Relacorilant 相关的新闻（医药）

2025-04-03

·药事纵横

3期新药临床成功，股价暴涨逾100%

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。近日，Corcept Therapeutics宣布其Relacorilant联合白蛋白结合型紫杉醇（nab-paclitaxel）治疗铂耐药卵巢癌患者的关键3期临床试验ROSELLA达到了改善无进展生存率的主要终点，这一结果由盲法独立中央审查（BICR）评估。基于这些发现，Corcept Therapeutics计划在2025年第3季度提交新药申请(NDA)，预计在2026/27年左右获得批准并推向市场。Truist Securities预测，到2035年，该药物的峰值销售额可能达到约8亿美元。此消息发布后（3月31日），公司股价涨幅最高逾110%，股价达到前所未有的里程碑。Relacorilant是一种口服治疗药物，是一种选择性糖皮质激素受体(GR)拮抗剂，通过与GR结合（但不与身体的其他激素受体结合）来调节皮质醇活性。除卵巢癌外，Corcept公司正在研究relacorilant在各种严重疾病中的作用，包括内源性皮质醇增多症（库欣综合征）和前列腺癌。此前，美国FDA已接受relacorilant用于治疗内源性高皮质醇症，又名库欣综合征的新药申请（NDA），PDUFA目标行动日期定为2025年12月30日。ROSELLA试验(ClinicalTrials.gov标识符：NCT05257408)在美国、欧洲、韩国、巴西、阿根廷、加拿大和澳大利亚的多个试验点招募了381名铂耐药卵巢癌患者。患者按 1:1 的比例随机分组，分别接受Relacorilant联合nab-paclitaxel治疗或仅接受nab-paclitaxel治疗。ROSELLA试验有两个主要终点——经盲态独立中心审查评估的无进展生存期（PFS-BICR）和总生存期（OS）。只要满足其中一个终点，即视为取得阳性结果。在ROSELLA试验中，与单独使用nab-paclitaxel治疗的患者相比，接受Relacorilant联合nab-paclitaxel治疗的患者疾病进展风险降低了30%（风险比：0.70；p值：0.008）。他们的中位PFS-BICR为6.5个月，而单独接受nab-paclitaxel治疗的患者为5.5个月。在对总体生存期（OS）的中期评估中，接受Relacorilant联合nab-paclitaxel治疗的患者OS显著改善，中位OS为16.0个月，而单独接受nab-paclitaxel治疗的患者为11.5个月（风险比：0.69；p值：0.012）。Relacorilant耐受性良好，未观察到新的安全信号。与公司2期试验的情况一样，两组的安全性和耐受性相当。ROSELLA的完整结果将在今年的医学会议上公布。该公司对铂耐药性卵巢癌患者进行的relacorilant第2期阶段试验结果于2023年6月在《临床肿瘤学杂志》上发表。25年多来，Corcept公司专注于皮质醇调节及其治疗多种严重疾病患者的潜力，已发现了1000多种专有选择性皮质醇调节剂和GR拮抗剂。科塞普特公司正在对皮质醇增多症、实体瘤、肌萎缩侧索硬化症（ALS）和肝病患者进行高级临床试验。2012年2月，该公司推出了Korlym®（米非司酮），这是美国食品药品监督管理局批准的第一种用于治疗内源性皮质醇增多症患者的药物。除Korlym（米非司酮）以外，Corcept还在开发新的选择性皮质醇调节剂。几款领先的在研药物已经进入临床，作为各种严重疾病的潜在治疗方法——库欣综合征、晚期卵巢癌、伴有皮质醇过量的肾上腺癌、前列腺癌、ALS（肌萎缩侧索硬化）和NASH（非酒精性脂肪性肝炎）等。2015年之后，Corcept Therapeutics 一直依靠Korlym的收入为运营提供资金。 2024年全年营收增长强劲,同比增长40%至6.75亿美元。净利润增长33%至1.41亿美元。尽管第四季度因药房合作伙伴运营问题面临挑战，公司仍继续保持其在皮质醇调节疗法领域的领先地位。截至2024年底，公司维持6.03亿美元的强劲现金储备。展望未来，Corcept预计2025年收入指引为9.00亿美元至9.50亿美元。参考资料：www.corcept.com-END-2025CMC-CHINA药博会 • 展位火热预定中！药事纵横投稿须知：稿费已上调，欢迎投稿各位朋友好，觉得本文对您有帮助，请随手点一下下方的在看，以便让你的朋友也能看到哦。

临床结果临床3期临床2期临床成功

2025-04-03

·癌度

《癌度早报2025年4月3日》

癌度临床试验病友交流群（点击）一、新药快讯1、国产口服KRAS基因G12D靶向药获批临床2025年4月1日，CDE官网显示，国产一类抗癌药HBW-012336获批临床，用于携带 KRAS G12D 突变的局部晚期或转移性实体瘤，这是该药在国内首次获批临床试验阶段，之前模型试验发现，HBW-012336 表现出显著的抗肿瘤药效，而且该药还可以与EGFR蛋白抗体药物西妥昔单抗协同使用，具有协同增效作用。2、ROS1靶向药他雷替尼疗效数据公布2025年欧洲肺癌大会上，在国内获批用于ROS1阳性肺癌的他雷替尼对比克唑替尼的研究数据公布，他雷替尼的治疗应答率达到了71.7%，而克唑替尼的治疗应答率为57.7%，与克唑替尼相比，他雷替尼使疾病进展风险降低52%，死亡风险降低66%，并且具有统计学显著意义。 3、国内首款实体瘤细胞疗法申报上市2025年4月1日，中国国家药监局药品审评中心（CDE）官网最新公示，爱可仑赛注射液上市申请获得受理。这是一种广谱性的细胞免疫治疗产品，为针对实体瘤的CIK疗法，该药在今年3月份被正式纳入优先审评，拟定的适应症为高复发风险的原发性肝细胞癌术后复发预防。二、新药快讯1、前沿药Relacorilant联合白蛋白紫杉醇，有效控制卵巢癌病情根据一项三期人体临床试验结果，前沿药Relacorilant联合白蛋白紫杉醇，相比单用白蛋白紫杉醇，在铂耐药卵巢癌患者中，显著改善了无进展生存时间，将中位无进展生存时间从5.5个月延长到6.5个月，将中位总生存时间从11.5个月延长到16个月，相比对照组，上述联合用药将疾病进展或死亡风险降低了30%。

优先审批临床3期免疫疗法细胞疗法申请上市

2025-04-01

·药明康德

晚期癌症患者缓解率提高3倍的双抗疗法；RNA编辑新锐完成1.55亿美元融资……

▎药明康德内容团队编辑总缓解率提高3倍！双特异性抗体疗法达到2/3期临床主要终点Compass Therapeutics今日宣布了2/3期临床试验COMPANION-002的积极结果。该研究评估了tovecimig（原名CTX-009）联合紫杉醇在晚期胆道癌（BTC）患者中的疗效。主要终点为总缓解率（ORR）。数据显示，在二线治疗的BTC患者中，tovecimig联合紫杉醇组的ORR为17.1%（19/111，其中1例完全缓解），而紫杉醇单药组ORR为5.3%（3/57）。联合治疗组较单药组ORR提高11.8%，达到统计学显著性（p=0.031）。Tovecimig是一种在研双特异性抗体，旨在同时阻断DLL4和VEGF-A信号通路。它的临床前及早期临床数据表明，双通路阻断在多种实体瘤中均展现出强大的抗肿瘤活性，包括结直肠癌、胃癌、胆管癌、胰腺癌和非小细胞肺癌。此外，在经过大量既往治疗且对获批抗VEGF疗法耐药的癌症患者中，tovecimig单药治疗已观察到部分患者获得缓解。1.55亿美元助力潜在“best-in-class”RNA编辑疗法进入临床AIRNA今日宣布完成超额认购的1.55亿美元B轮融资。该公司将利用本轮融资获得的资金推动其针对α1抗胰蛋白酶缺乏症（AATD）的首个RNA编辑候选药物AIR-001进入1/2期临床试验，并开发针对心血管代谢及其他疾病的一系列创新RNA编辑药物。AIRNA的独有平台利用天然机制以安全灵活的药物高效编辑目标RNA。精准的RNA编辑旨在通过修复有害基因变异或引入有益变异来实现对严重或慢性疾病的功能性治愈。新闻稿指出，该公司的主打项目有望成为治疗α1抗胰蛋白酶缺乏症的潜在“best-in-class”疗法。德国默克获得和誉医药小分子疗法匹米替尼全球开发权益和誉医药今日宣布，德国默克（Merck KGaA）已根据双方于2023年12月签订的授权协议，行使在研药物匹米替尼（pimicotinib）的全球商业化选择权，行权费用为8500万美元。此外，德国默克可选择在若干条件下共同开发匹米替尼的其它适应症。和誉医药可获得高达6.055亿美元的款项，包括首付款，以及开发和商业化里程碑付款。匹米替尼是一款全新的口服、高选择性、高活性CSF-1R小分子抑制剂。该产品曾获美国FDA授予突破性疗法认定和快速通道资格，用于治疗不可手术切除的腱鞘巨细胞瘤。和誉医药近日宣布，评估匹米替尼治疗腱鞘巨细胞瘤的3期MANEUVER研究在第25周客观缓解率方面取得了统计学意义上的显著改善，达到54.0%，而安慰剂为3.2%。降低卵巢癌疾病进展风险30%，创新小分子即将递交上市申请Corcept Therapeutics日前宣布，其关键性3期临床试验ROSELLA达到主要终点，在研疗法relacorilant联合紫杉醇，治疗对铂类化疗耐药的卵巢癌患者可改善无进展生存期（PFS）。基于这一积极结果，该公司计划向美国和欧盟的监管机构递交上市申请。在ROSELLA试验中，与单用紫杉醇的患者相比，接受relacorilant组合疗法的患者其疾病进展风险降低30%（HR=0.70；p=0.008）。联合治疗组的PFS为6.5个月，而紫杉醇单药组为5.5个月。在总生存期（OS）的中期评估中，联合治疗组患者的中位OS显著延长，为16.0个月，而紫杉醇单药组为11.5个月（HR=0.69；p=0.012）。此外，relacorilant耐受性良好，未观察到新的安全信号。Relacorilant是一种口服选择性糖皮质激素受体（GR）拮抗剂，通过与GR结合而非体内其他激素受体结合来调节皮质醇活性。它已获得欧盟委员会（EC）授予的孤儿药资格，用于治疗卵巢癌。▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料：[1] Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer. Retrieved April 1, 2025, from https://investors.compasstherapeutics.com/news-releases/news-release-details/tovecimig-ctx-009-meets-primary-endpoint-ongoing-randomized[2] AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline. Retrieved April 1, 2025, from https://www.businesswire.com/news/home/20250401473885/en/AIRNA-Raises-Oversubscribed-%24155-Million-Series-B-Financing-to-Fund-Phase-12-Clinical-Trial-for-Alpha-1-Antitrypsin-Deficiency-and-Future-Pipeline[3] Merck exercised the option for the global rights of Abbisko Therapeutics’ pimicotinib. Retrieved April 1, 2025, from https://www.abbisko.com/newsDetail/203.html[4] Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer. Retrieved April 1, 2025, from https://www.businesswire.com/news/home/20250331748780/en/Primary-Endpoint-Met-in-Corcepts-Pivotal-Phase-3-ROSELLA-Trial-of-Relacorilant-in-Patients-with-Platinum-Resistant-Ovarian-Cancer免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

突破性疗法引进/卖出快速通道临床1期临床2期

100 项与 Relacorilant 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11336	Relacorilant	-	DB14976

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
库欣综合征	申请上市	美国	Corcept Therapeutics, Inc.	2024-12-30
腹膜癌	临床3期	美国	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	阿根廷	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	澳大利亚	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	比利时	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	巴西	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	加拿大	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	法国	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	匈牙利	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	以色列	Corcept Therapeutics, Inc.	2022-06-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03697109 (GRACE, CTgov)	临床3期	内源性库欣综合征	152	Relacorilant (Relacorilant (RW Phase))	鑰齋製繭遞鏇鏇選繭製 = 廠壓選蓋遞憲衊選憲築鹹鬱齋構範構顧蓋膚衊 (窪鏇膚遞簾築艱獵壓壓, 獵膚製網膚憲壓鹽鏇夢 ~ 繭鑰獵顧範築顧蓋製憲) 更多	-	2025-04-24
				Placebo (Placebo (RW Phase))	鑰齋製繭遞鏇鏇選繭製 = 夢壓醖觸壓顧遞遞齋齋鹹鬱齋構範構顧蓋膚衊 (窪鏇膚遞簾築艱獵壓壓, 蓋餘膚齋選鹽壓觸獵廠 ~ 構鹹膚繭夢艱鑰鹹艱壓) 更多
NCT05257408 (ROSELLA, Company_Website) 人工标引	临床3期	铂耐药性卵巢癌	381	Relacorilant + nab-paclitaxel	餘鑰鑰窪膚積獵鹹餘積(窪衊積觸顧範齋鹽築範) = 選選衊艱蓋鬱築艱鹽鏇繭憲醖網餘齋觸簾衊鏇 (鹽製構繭餘遞繭衊餘窪 ) 达到更多	积极	2025-03-31
				Nab-paclitaxel	餘鑰鑰窪膚積獵鹹餘積(窪衊積觸顧範齋鹽築範) = 膚壓繭蓋蓋簾願築願淵繭憲醖網餘齋觸簾衊鏇 (鹽製構繭餘遞繭衊餘窪 ) 达到更多
NCT03604198 (BusinessWire) 人工标引	临床3期	库欣综合征	116	Relacorilant	遞願鏇獵膚醖鏇築憲網(膚壓蓋築衊築鏇襯鏇構) = At month 24 of the study, patients exhibited clinically meaningful and statistically significant reductions in mean systolic blood pressure (10.0 mm Hg; p-value: 0.012) and mean diastolic blood pressure (7.3 mm Hg; p-value: 0.016), compared to their measurement at entry into the long-term extension study. 鏇獵網構衊淵齋願構簾 (醖淵獵遞廠醖壓艱獵顧 ) 更多	积极	2024-12-16
NCT03604198 (Company_Website) 人工标引	临床2期	库欣综合征	53	Relacorilant	膚襯憲廠壓簾廠選網齋(艱鑰壓遞鬱鹽憲製膚齋) = 憲獵鏇遞選齋願衊範構齋積鏇顧醖夢築廠願範 (範築繭艱衊觸夢遞齋餘 ) 更多	积极	2024-11-25
NCT04308590 (GRADIENT, Biospace) 人工标引	临床3期	库欣综合征	137	relacorilant	膚積醖簾糧製鹽襯淵夢(糧顧鏇廠鑰窪鬱鹹淵網) = 齋積構廠鏇遞窪觸夢壓鹹繭夢鹽糧淵襯壓繭鑰 (淵廠鏇艱獵製範壓窪憲 ) 达到	积极	2024-10-30
				Placebo	膚積醖簾糧製鹽襯淵夢(糧顧鏇廠鑰窪鬱鹹淵網) = 築鑰願窪簾醖構獵憲簾鹹繭夢鹽糧淵襯壓繭鑰 (淵廠鏇艱獵製範壓窪憲 ) 达到
NCT02804750 \| NCT00280475 (Pubmed \| J Endocrinol Invest)	临床2期	库欣综合征 factor VIII \| activated partial thromboplastin time \| platelet count ... 更多	34	Relacorilant (Surgery)	範積壓餘製艱夢膚鏇構(築餘憲鑰膚鬱製構築醖) = 鹹淵築鏇淵鏇糧淵壓齋鬱齋鹽鏇願鏇築齋鹽顧 (餘廠膚衊獵積構窪衊蓋 )	积极	2024-09-21
NCT03697109 (GRACE, ENDO2024)	临床3期	库欣综合征	152	Relacorilant 100 mg QD	餘願鏇窪積網鹽鬱獵構(繭製淵衊網繭遞鏇夢築) = 製觸糧顧簾齋顧艱製願獵鑰糧製築顧壓顧憲壓 (廠齋鏇夢餘鏇壓繭網網, 6.7) 更多	积极	2024-06-01
NCT03697109 (GRACE, Company_Website) 人工标引	临床3期	库欣综合征	-	relacorilant	鑰製繭襯築蓋淵醖廠範(築鏇構糧齋網願鹽夢繭) = GRACE met its primary endpoint of loss of blood pressure control in the randomized withdrawal phase among patients receiving relacorilant as compared to placebo 壓鹽網簾鬱餘顧選齋鏇 (遞觸願鹽製願壓鹽淵窪 ) 达到更多	积极	2024-05-28
				placebo
NCT03697109 (GRACE, GlobeNewswire) 人工标引	临床3期	内源性库欣综合征	152	relacorilant	淵範獵淵壓憲範構鏇艱(遞壓糧鏇網願積鑰壓觸) = 範簾積窪夢鬱憲網鹽廠糧製齋艱顧觸鏇醖蓋憲 (膚構餘鏇獵顧壓遞齋糧 ) 更多	积极	2024-04-22
				relacorilant (withdrawal phase)	淵範獵淵壓憲範構鏇艱(遞壓糧鏇網願積鑰壓觸) = 鹽獵醖衊範遞範壓範願糧製齋艱顧觸鏇醖蓋憲 (膚構餘鏇獵顧壓遞齋糧 ) 更多
NCT04329949 (RELIANT, CTgov)	临床3期	转移性胰腺导管腺癌	43	Nab-paclitaxel+25 mg	簾選選鹽構膚遞網遞積 = 顧顧簾觸選壓遞廠選夢壓獵鏇願艱淵觸鬱壓齋 (衊夢淵壓鹽鑰構夢簾遞, 衊鏇構築夢鏇廠範餘構 ~ 繭餘鬱餘淵醖簾製繭顧) 更多	-	2023-11-18